Haw ParHAWPF 95 Altman Z-Score is 18.38 as of Jun. 27, 2026, which is 16% above its 10-year median of 15.89. GuruFocus rates HAWPF with a GF Score™ of 95/100 and a GF Value™ of $8.79. The stock has 3 warning signs investors should review. Among 952 Drug Manufacturers companies, Haw Par ranks better than 94.54% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 18.74 is strong.
Haw Par has a Altman Z-Score of 18.38, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Haw Par's Altman Z-Score or its related term are showing as below:
HAWPF'
s Altman Z-Score Range Over the Past 10 Years
Min: 9.32 Med: 15.89 Max: 24.28
Current: 18.74
During the past 13 years, Haw Par's highest Altman Z-Score was 24.28. The lowest was 9.32. And the median was 15.89.
Haw Par (OTCPK:HAWPF) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Haw Par Altman Z-Score Related Terms
Haw Par Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Haw Par's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAWPF vs LLY, JNJ, ABBV: Altman Z-Score Comparison
For the Drug Manufacturers - General subindustry, Haw Par's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Haw Par's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Haw Par's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.9426
+
1.4
*
0.3473
+
3.3
*
0.0641
+
0.6
*
27.5015
+
1.0
*
0.0521
=
18.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Haw Par (HAWPF) has a Altman Z-Score of 18.38 as of Jun. 27, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Haw Par and its competitors. This is 16% above median its historical median of 15.89. Over the past decade, Haw Par's Altman Z-Score has ranged from 9.32 to 24.28. According to the industry distribution chart, Haw Par ranks #52 out of 952 companies in the Drug Manufacturers industry, placing it in the top 5.5%.
Is Haw Par's Altman Z-Score too high?
Haw Par's current Altman Z-Score of 18.38 is 16% above median its 10-year median of 15.89. Over the past 10 years, this metric has ranged from a low of 9.32 to a high of 24.28. The Drug Manufacturers industry median Altman Z-Score is 3.30. Haw Par's value of 18.38 is 457.8% above this industry median. Based on the distribution chart, Haw Par ranks #52 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haw Par has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Haw Par's Altman Z-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #52 out of 952 companies for Altman Z-Score. This places Haw Par in the top 6% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.30. Haw Par's value of 18.38 is 457.8% above this benchmark. Historically, Haw Par's own Altman Z-Score has ranged from 9.32 to 24.28 over the past decade. While the company's 10-year median is 15.89 vs. the industry median of 3.30, Haw Par has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current Altman Z-Score of 18.38 is 457.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current Altman Z-Score is 18.38, which is 16% above median its own 10-year median of 15.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Haw Par (HAWPF) has a current Altman Z-Score of 18.38. The stock's GF Value™ is $8.79, compared to a current price of $12.00 — trading 36.5% above its estimated fair value. The current Altman Z-Score is 18.38, which is 16% above median its 10-year median of 15.89 and 457.8% above the Drug Manufacturers industry median of 3.30. Haw Par's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Haw Par (HAWPF), the current Altman Z-Score is 18.38 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.00 is trading 36.5% above its estimated GF Value™ of $8.79.
Key valuation signals for HAWPF:
Altman Z-Score: 18.38 (16% above median its 10-year median of 15.89)
GF Value™: $8.79 vs. price of $12.00 (36.5% above fair value)
Industry Position: 457.8% above the Drug Manufacturers median (#52 of 952)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
95GF Score
Get the complete analysis for HAWPF
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
